Journal ArticleOPEN ACCESS

Unpicking the combination lock for mutant BRAF and RAS melanomas

Cancer Discovery (2013) 3(1) 13-19
DOI: 10.1158/2159-8290.CD-12-0520
4Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

Large-scale, unbiased combinatorial drug screening has been used to identify effective genotypeselective therapeutic combinations that show promising activity in preclinical models of mutant BRAF and RAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib. © 2012 American Association for Cancer Research.

Cite

CITATION STYLE

APA

Al-Lazikani, B., & Workman, P. (2013). Unpicking the combination lock for mutant BRAF and RAS melanomas. Cancer Discovery, 3(1), 13–19. https://doi.org/10.1158/2159-8290.CD-12-0520

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free